-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image source: COO
Recently, a retrospective study published in Sleep magazine revealed the relationship between OSA and the risk of dementia.
OSA patients receiving positive airway pressure (PAP) treatment can significantly reduce the incidence of Alzheimer's disease and other types of dementia in the elderly.
In this study, researchers from the Sleep Disorder Research Center of the Medical College of Michigan analyzed the Medicare health insurance data of 53,321 people over 65 who were diagnosed with OSA, and explored the positive airway pressure (PAP) treatment and the next 3 years.
The association between Alzheimer's disease (AD), mild cognitive impairment (MCI) and non-specific dementia (DNOS).
The results of the study show that there is a significant correlation between the use of positive airway pressure (PAP) and the risk of Alzheimer’s disease and other types of dementia within 3 years, indicating that PAP therapy may prevent dementia in patients with OSA risk.
Specifically, 78% of OSA patients benefited from PAP treatment, and 74% showed evidence of adherence to PAP.
After adjusting for confounding factors, PAP treatment was associated with a lower incidence of AD and DNOS (OR=0.
78, 95%CI: 0.
69-0.
89; OR=0.
69, 95%CI: 0.
55-0.
85).
A lower probability of MCI was also observed in PAP users (OR=0.
82, 95% CI: 0.
66-1.
02).
At the same time, PAP compliance was associated with a lower diagnosis probability of AD events (OR=0.
65, 95% CI: 0.
56-0.
76).
Researchers said that although OSA has extensive, long-term and serious harm to the body, in clinical practice, the diagnosis and treatment of OSA-related diseases lack the necessary attention.
If there is a causal relationship between OSA treatment and the risk of dementia, the diagnosis and effective treatment of OSA may play a key role in the cognitive health of the elderly.
Original source
GL Dunietz et al, Obstructive Sleep Apnea Treatment and Dementia Risk in Older Adults, Sleep (2021).
DOI: 10.
1093/sleep/zsab076
The association between Alzheimer's disease (AD), mild cognitive impairment (MCI) and non-specific dementia (DNOS).
The results of the study show that there is a significant correlation between the use of positive airway pressure (PAP) and the risk of Alzheimer’s disease and other types of dementia within 3 years, indicating that PAP therapy may prevent dementia in patients with OSA risk.
Specifically, 78% of OSA patients benefited from PAP treatment, and 74% showed evidence of adherence to PAP.
After adjusting for confounding factors, PAP treatment was associated with a lower incidence of AD and DNOS (OR=0.
78, 95%CI: 0.
69-0.
89; OR=0.
69, 95%CI: 0.
55-0.
85).
A lower probability of MCI was also observed in PAP users (OR=0.
82, 95% CI: 0.
66-1.
02).
At the same time, PAP compliance was associated with a lower diagnosis probability of AD events (OR=0.
65, 95% CI: 0.
56-0.
76).
Researchers said that although OSA has extensive, long-term and serious harm to the body, in clinical practice, the diagnosis and treatment of OSA-related diseases lack the necessary attention.
If there is a causal relationship between OSA treatment and the risk of dementia, the diagnosis and effective treatment of OSA may play a key role in the cognitive health of the elderly.
Original source
GL Dunietz et al, Obstructive Sleep Apnea Treatment and Dementia Risk in Older Adults, Sleep (2021).
DOI: 10.
1093/sleep/zsab076
In this study, researchers from the Sleep Disorder Research Center of the Medical College of Michigan analyzed the Medicare health insurance data of 53,321 people over 65 who were diagnosed with OSA, and explored the positive airway pressure (PAP) treatment and the next 3 years.
The association between Alzheimer's disease (AD), mild cognitive impairment (MCI) and non-specific dementia (DNOS).
The results of the study show that there is a significant correlation between the use of positive airway pressure (PAP) and the risk of Alzheimer’s disease and other types of dementia within 3 years, indicating that PAP therapy may prevent dementia in patients with OSA risk.
Specifically, 78% of OSA patients benefited from PAP treatment, and 74% showed evidence of adherence to PAP.
After adjusting for confounding factors, PAP treatment was associated with a lower incidence of AD and DNOS (OR=0.
78, 95%CI: 0.
69-0.
89; OR=0.
69, 95%CI: 0.
55-0.
85).
A lower probability of MCI was also observed in PAP users (OR=0.
82, 95% CI: 0.
66-1.
02).
At the same time, PAP compliance was associated with a lower diagnosis probability of AD events (OR=0.
65, 95% CI: 0.
56-0.
76).
Researchers said that although OSA has extensive, long-term and serious harm to the body, in clinical practice, the diagnosis and treatment of OSA-related diseases lack the necessary attention.
If there is a causal relationship between OSA treatment and the risk of dementia, the diagnosis and effective treatment of OSA may play a key role in the cognitive health of the elderly.
Original source
GL Dunietz et al, Obstructive Sleep Apnea Treatment and Dementia Risk in Older Adults, Sleep (2021).
DOI: 10.
1093/sleep/zsab076
Diagnosis, The association between Alzheimer's disease (AD), mild cognitive impairment (MCI) and non-specific dementia (DNOS).
The results of the study show that there is a significant correlation between the use of positive airway pressure (PAP) and the risk of Alzheimer’s disease and other types of dementia within 3 years, indicating that PAP therapy may prevent dementia in patients with OSA risk.
Specifically, 78% of OSA patients benefited from PAP treatment, and 74% showed evidence of adherence to PAP.
After adjusting for confounding factors, PAP treatment was associated with a lower incidence of AD and DNOS (OR=0.
78, 95%CI: 0.
69-0.
89; OR=0.
69, 95%CI: 0.
55-0.
85).
A lower probability of MCI was also observed in PAP users (OR=0.
82, 95% CI: 0.
66-1.
02).
At the same time, PAP compliance was associated with a lower diagnosis probability of AD events (OR=0.
65, 95% CI: 0.
56-0.
76).
Researchers said that although OSA has extensive, long-term and serious harm to the body, in clinical practice, the diagnosis and treatment of OSA-related diseases lack the necessary attention.
If there is a causal relationship between OSA treatment and the risk of dementia, the diagnosis and effective treatment of OSA may play a key role in the cognitive health of the elderly.
Original source
GL Dunietz et al, Obstructive Sleep Apnea Treatment and Dementia Risk in Older Adults, Sleep (2021).
DOI: 10.
1093/sleep/zsab076
diagnosis,
diagnosis
